...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>The Prostate >Time course of serum testosterone and luteinizing hormone levels after cessation of long-term luteinizing hormone-releasing hormone agonist treatment in patients with prostate cancer.
【24h】

Time course of serum testosterone and luteinizing hormone levels after cessation of long-term luteinizing hormone-releasing hormone agonist treatment in patients with prostate cancer.

机译：前列腺癌患者长期停止黄体生成激素释放激素激动剂治疗后血清睾丸激素和黄体生成激素水平的时程。

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

INTRODUCTION: In order to elucidate the influence of hormone-releasing hormone (LH-RH) agonist therapy cessation on pituitary/testicular function and its clinical implications, we investigated prospectively hormonal (luteinizing hormone: LH; testosterone: T) responses in patients with prostate cancer who received long-term LH-RH 10 agonist therapy. PATIENTS AND METHODS: A consecutive 32 patients who had received LH-RH agonist therapy over 24 months were enrolled. As a baseline, T and LH were measured at the time of LH-RH agonist therapy cessation, monthly for 3 months, and subsequently, every 3 months. RESULTS: The median duration of LH-RH agonist therapy was 30 months (24-87 months) with median follow-up duration of 24 months following cessation. All patients had castrated T levels and suppressed LH levels at baseline. Median duration of castrated T levels following cessation was 6 months. Median time to normalization of T levels was 24 months. LH levels returned to normal within 3 months in all cases. Patients who received androgen deprivation therapy for 30 months or longer required a longer time for recovery of T levels. Patients over 65 years of age showed a statistically significant longer time for recovery of T levels (P=0.0167). CONCLUSIONS: Long-term LH-RH agonist therapy has remarkable effects on serum T level that last for a significant time after cessation, a fact that should be applied to the interpretation of both PSA and serum T levels after cessation of androgen deprivation therapy.
机译：简介：为了阐明激素释放激素（LH-RH）激动剂治疗中止对垂体/睾丸功能的影响及其临床意义，我们对前列腺患者的激素（促黄体生成素：LH;睾丸激素：T）反应进行了前瞻性研究。长期接受LH-RH 10激动剂治疗的癌症。病人和方法：连续24个月接受LH-RH激动剂治疗的32例患者入选。作为基线，在停止LH-RH激动剂治疗时（每月3个月，随后每3个月）测量T和LH。结果：LH-RH激动剂治疗的中位时间为30个月（24-87个月），中位随访时间为停药后24个月。所有患者基线时baseline割T水平并抑制LH水平。戒断后cast割T水平的中位持续时间为6个月。 T水平正常化的中位时间为24个月。在所有情况下，LH水平在3个月内恢复正常。接受雄激素剥夺疗法30个月或更长时间的患者需要更长的时间来恢复T水平。 65岁以上的患者表现出恢复T水平的统计学上更长的时间（P = 0.0167）。结论：长期LH-RH激动剂治疗对血清T水平有显着影响，在停止后可持续相当长的时间，这一事实应被用于在停止雄激素剥夺治疗后对PSA和血清T水平的解释。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号